A 7.0-7.7% value for glycated haemoglobin is better than a <7% value as an appropriate target for patient-centered drug treatment of type 2 diabetes mellitus

被引：4
作者：
Nunes, Jose Pedro L. [1 ]
DeMarco, Joseph P. [2 ]
机构：
[1] Univ Porto, Fac Med, Dept Med, Porto, Portugal
[2] Cleveland State Univ, Dept Philosophy, Cleveland, OH 44115 USA
来源：
ANNALS OF TRANSLATIONAL MEDICINE | 2019年 / 7卷
关键词：
BLOOD-GLUCOSE CONTROL; CARDIOVASCULAR OUTCOMES; VASCULAR COMPLICATIONS; EUROPEAN ASSOCIATION; POSITION STATEMENT; FOLLOW-UP; MORTALITY; RISK; HYPERGLYCEMIA; MANAGEMENT;
D O I：
10.21037/atm.2019.05.43
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：9
相关论文
共 38 条
  • [1] [Anonymous], NEW ENGL J MED
  • [2] [Anonymous], BIOETHICS CONTEXT MO
  • [3] Mortality Rates in Trials of Subjects With Type 2 Diabetes
    Barkoudah, Ebrahim
    Skali, Hicham
    Uno, Hajime
    Solomon, Scott D.
    Pfeffer, Marc A.
    [J]. JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2012, 1 (01): : 8 - 15
  • [4] Bariatric surgery: A systematic review and meta-analysis
    Buchwald, H
    Avidor, Y
    Braunwald, E
    Jensen, MD
    Pories, W
    Fahrbach, K
    Schoelles, K
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 292 (14): : 1724 - 1737
  • [5] Glycemic Targets: Standards of Medical Care in Diabetes-2019
    Cefalu, William T.
    Berg, Erika Gebel
    Saraco, Mindy
    Petersen, Matthew P.
    Uelmen, Sacha
    Robinson, Shamera
    [J]. DIABETES CARE, 2019, 42 : S61 - S70
  • [6] Survival as a function of HbA1c in people with type 2 diabetes: a retrospective cohort study
    Currie, Craig J.
    Peters, John R.
    Tynan, Aodan
    Evans, Marc
    Heine, Robert J.
    Bracco, Oswaldo L.
    Zagar, Tony
    Poole, Chris D.
    [J]. LANCET, 2010, 375 (9713) : 481 - 489
  • [7] Is There an Ethical Obligation to Disclose Controversial Risk? A Question From the ACCORD Trial
    DeMarco, Joseph P.
    Ford, Paul J.
    Patton, Dana J.
    Stewart, Douglas O.
    [J]. AMERICAN JOURNAL OF BIOETHICS, 2014, 14 (04) : 4 - 10
  • [8] Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events):: a randomised controlled trial
    Dormandy, JA
    Charbonnel, B
    Eckland, DJA
    Erdmann, E
    Massi-Benedetti, M
    Kmoules, IK
    Skene, AM
    Tan, MH
    Lefébvre, PJ
    Murray, GD
    Standl, E
    Wilcox, RG
    Wlhelmsen, L
    Betteridge, J
    Birkeland, K
    Golay, A
    Heine, RJ
    Korányi, L
    Laakso, M
    Mokán, M
    Norkus, A
    Pirags, V
    Podar, T
    Scheen, A
    Scherbaum, W
    Schernthaner, G
    Schmitz, O
    Skrha, J
    Smith, U
    Taton, J
    [J]. LANCET, 2005, 366 (9493) : 1279 - 1289
  • [9] Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes
    Duckworth, William
    Abraira, Carlos
    Moritz, Thomas
    Reda, Domenic
    Emanuele, Nicholas
    Reaven, Peter D.
    Zieve, Franklin J.
    Marks, Jennifer
    Davis, Stephen N.
    Hayward, Rodney
    Warren, Stuart R.
    Goldman, Steven
    McCarren, Madeline
    Vitek, Mary Ellen
    Henderson, William G.
    Huang, Grant D.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2009, 360 (02) : 129 - U62
  • [10] Gerstein HC, 2008, NEW ENGL J MED, V358, P2545, DOI 10.1056/NEJMoa0802743
1234